The present invention relates to the compositions containing dicycloplatin, pharmaceutical use of the compositions in the treatment and/or prevention of pain, inflammation and virus-related diseases, and methods of preparing the compostions thereof.

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.

The invention discloses a method for preparing maleate by selective catalytic oxidation of lignin. The method uses a heteropolyacid functionalized ionic liquid as a catalyst, and an aqueous alcohol solution as a reaction medium to achieve high-efficiency selective catalytic conversion and ring opening oxidation of biomass lignin at a reaction temperature of 110-160 C. and an oxygen pressure of 0.5-1.0 MPa for 1-6 h. The selectivity of maleate is higher than 47.83%. The yield and selectivity of a single chemical derived from the depolymerization of lignin in the present invention are much higher than the prior art, and the ionic liquid catalyst exhibits outstanding advantages such as availability of recovery and recycling through simple temperature adjustment; the reaction conditions of the present invention are mild, and the process is green and safe, easy to operate, and available for batch and continuous production. The invention provides a new green way for preparing bulk chemicals like maleate from reproducible raw materials such as lignin.

The invention discloses a method for preparing maleate by selective catalytic oxidation of lignin. The method uses a heteropolyacid functionalized ionic liquid as a catalyst, and an aqueous alcohol solution as a reaction medium to achieve high-efficiency selective catalytic conversion and ring opening oxidation of biomass lignin at a reaction temperature of 110-160 C. and an oxygen pressure of 0.5-1.0 MPa for 1-6 h. The selectivity of maleate is higher than 47.83%. The yield and selectivity of a single chemical derived from the depolymerization of lignin in the present invention are much higher than the prior art, and the ionic liquid catalyst exhibits outstanding advantages such as availability of recovery and recycling through simple temperature adjustment; the reaction conditions of the present invention are mild, and the process is green and safe, easy to operate, and available for batch and continuous production. The invention provides a new green way for preparing bulk chemicals like maleate from reproducible raw materials such as lignin.

The present invention relates to crystalline forms of Afatinib and its dimaleate salt. The present invention also relates to processes for the preparation of crystalline forms of Afatinib and its dimaleate salt. The present invention further relates to pharmaceutical compositions of such crystalline forms of Afatinib dimaleate and use thereof in the treatment of a patient in need thereof.

The present invention relates to crystalline forms of Afatinib and its dimaleate salt. The present invention also relates to processes for the preparation of crystalline forms of Afatinib and its dimaleate salt. The present invention further relates to pharmaceutical compositions of such crystalline forms of Afatinib dimaleate and use thereof in the treatment of a patient in need thereof.

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.

The present application relates to maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)aniline]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, crystalline forms thereof, to processes for its preparation, to pharmaceutical compositions comprising it and to its use in the control of disorders.